

Bioengineered Protein Drugs-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/BD3D6861F06EN.html>

Date: February 2018

Pages: 153

Price: US\$ 3,480.00 (Single User License)

ID: BD3D6861F06EN

Abstracts

Report Summary

Bioengineered Protein Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bioengineered Protein Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Bioengineered Protein Drugs 2013-2017, and development forecast 2018-2023

Main market players of Bioengineered Protein Drugs in Europe, with company and product introduction, position in the Bioengineered Protein Drugs market

Market status and development trend of Bioengineered Protein Drugs by types and applications

Cost and profit status of Bioengineered Protein Drugs, and marketing status

Market growth drivers and challenges

The report segments the Europe Bioengineered Protein Drugs market as:

Europe Bioengineered Protein Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Bioengineered Protein Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Therapeutic Proteins

Monoclonal Antibodies

Vaccines

Europe Bioengineered Protein Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Diabetes and Hormonal Disorders

Genetic and Fertility Disorders

Cancers

Organ Transplants

Others

Europe Bioengineered Protein Drugs Market: Players Segment Analysis (Company and
Product introduction, Bioengineered Protein Drugs Sales Volume, Revenue, Price and
Gross Margin):

Abbott Laboratories

F. Hoffmann-La Roche Ltd

Amgen, Inc.

Bayer AG

Merck & Co., Inc.

Dr. Reddy's Laboratories Ltd.

Biocon Ltd.

Eli Lilly and Company

Sanofi

GlaxoSmithKline plc

Johnson & Johnson

JanssenNovartis AG

Panacea Biotec

ProBioGen AG

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BIOENGINEERED PROTEIN DRUGS

- 1.1 Definition of Bioengineered Protein Drugs in This Report
- 1.2 Commercial Types of Bioengineered Protein Drugs
 - 1.2.1 Therapeutic Proteins
 - 1.2.2 Monoclonal Antibodies
 - 1.2.3 Vaccines
- 1.3 Downstream Application of Bioengineered Protein Drugs
 - 1.3.1 Diabetes and Hormonal Disorders
 - 1.3.2 Genetic and Fertility Disorders
 - 1.3.3 Cancers
 - 1.3.4 Organ Transplants
 - 1.3.5 Others
- 1.4 Development History of Bioengineered Protein Drugs
- 1.5 Market Status and Trend of Bioengineered Protein Drugs 2013-2023
 - 1.5.1 Europe Bioengineered Protein Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Bioengineered Protein Drugs Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Bioengineered Protein Drugs in Europe 2013-2017
- 2.2 Consumption Market of Bioengineered Protein Drugs in Europe by Regions
 - 2.2.1 Consumption Volume of Bioengineered Protein Drugs in Europe by Regions
 - 2.2.2 Revenue of Bioengineered Protein Drugs in Europe by Regions
- 2.3 Market Analysis of Bioengineered Protein Drugs in Europe by Regions
 - 2.3.1 Market Analysis of Bioengineered Protein Drugs in Germany 2013-2017
 - 2.3.2 Market Analysis of Bioengineered Protein Drugs in United Kingdom 2013-2017
 - 2.3.3 Market Analysis of Bioengineered Protein Drugs in France 2013-2017
 - 2.3.4 Market Analysis of Bioengineered Protein Drugs in Italy 2013-2017
 - 2.3.5 Market Analysis of Bioengineered Protein Drugs in Spain 2013-2017
 - 2.3.6 Market Analysis of Bioengineered Protein Drugs in Benelux 2013-2017
 - 2.3.7 Market Analysis of Bioengineered Protein Drugs in Russia 2013-2017
- 2.4 Market Development Forecast of Bioengineered Protein Drugs in Europe 2018-2023
 - 2.4.1 Market Development Forecast of Bioengineered Protein Drugs in Europe 2018-2023
 - 2.4.2 Market Development Forecast of Bioengineered Protein Drugs by Regions 2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of Bioengineered Protein Drugs in Europe by Types

3.1.2 Revenue of Bioengineered Protein Drugs in Europe by Types

3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

3.3 Market Forecast of Bioengineered Protein Drugs in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Bioengineered Protein Drugs in Europe by Downstream Industry

4.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Germany

4.2.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in United Kingdom

4.2.3 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in France

4.2.4 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Italy

4.2.5 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Spain

4.2.6 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Benelux

4.2.7 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Russia

4.3 Market Forecast of Bioengineered Protein Drugs in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOENGINEERED PROTEIN DRUGS

5.1 Europe Economy Situation and Trend Overview

5.2 Bioengineered Protein Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 BIOENGINEERED PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

6.1 Sales Volume of Bioengineered Protein Drugs in Europe by Major Players

6.2 Revenue of Bioengineered Protein Drugs in Europe by Major Players

6.3 Basic Information of Bioengineered Protein Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Bioengineered Protein Drugs Major Players

6.3.2 Employees and Revenue Level of Bioengineered Protein Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 BIOENGINEERED PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Abbott Laboratories

7.1.1 Company profile

7.1.2 Representative Bioengineered Protein Drugs Product

7.1.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories

7.2 F. Hoffmann-La Roche Ltd

7.2.1 Company profile

7.2.2 Representative Bioengineered Protein Drugs Product

7.2.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd

7.3 Amgen, Inc.

7.3.1 Company profile

7.3.2 Representative Bioengineered Protein Drugs Product

7.3.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc.

7.4 Bayer AG

7.4.1 Company profile

7.4.2 Representative Bioengineered Protein Drugs Product

- 7.4.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
- 7.5 Merck & Co., Inc.
 - 7.5.1 Company profile
 - 7.5.2 Representative Bioengineered Protein Drugs Product
 - 7.5.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
- 7.6 Dr. Reddy's Laboratories Ltd.
 - 7.6.1 Company profile
 - 7.6.2 Representative Bioengineered Protein Drugs Product
 - 7.6.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd.
- 7.7 Biocon Ltd.
 - 7.7.1 Company profile
 - 7.7.2 Representative Bioengineered Protein Drugs Product
 - 7.7.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd.
- 7.8 Eli Lilly and Company
 - 7.8.1 Company profile
 - 7.8.2 Representative Bioengineered Protein Drugs Product
 - 7.8.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
- 7.9 Sanofi
 - 7.9.1 Company profile
 - 7.9.2 Representative Bioengineered Protein Drugs Product
 - 7.9.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi
- 7.10 GlaxoSmithKline plc
 - 7.10.1 Company profile
 - 7.10.2 Representative Bioengineered Protein Drugs Product
 - 7.10.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
- 7.11 Johnson & Johnson
 - 7.11.1 Company profile
 - 7.11.2 Representative Bioengineered Protein Drugs Product
 - 7.11.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.12 JanssenNovartis AG
 - 7.12.1 Company profile
 - 7.12.2 Representative Bioengineered Protein Drugs Product

7.12.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG

7.13 Panacea Biotec

7.13.1 Company profile

7.13.2 Representative Bioengineered Protein Drugs Product

7.13.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec

7.14 ProBioGen AG

7.14.1 Company profile

7.14.2 Representative Bioengineered Protein Drugs Product

7.14.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOENGINEERED PROTEIN DRUGS

8.1 Industry Chain of Bioengineered Protein Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOENGINEERED PROTEIN DRUGS

9.1 Cost Structure Analysis of Bioengineered Protein Drugs

9.2 Raw Materials Cost Analysis of Bioengineered Protein Drugs

9.3 Labor Cost Analysis of Bioengineered Protein Drugs

9.4 Manufacturing Expenses Analysis of Bioengineered Protein Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOENGINEERED PROTEIN DRUGS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Bioengineered Protein Drugs-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BD3D6861F06EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BD3D6861F06EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970